<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04194021</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00027582</org_study_id>
    <nct_id>NCT04194021</nct_id>
  </id_info>
  <brief_title>Characteristics and Outcomes of Patients Who Received Etravirine and/or Darunavir</brief_title>
  <official_title>Demographic, Clinical, and Laboratory Characteristics and Outcomes of Patients Who Ever Received Etravirine and/or Darunavir - Multi-country Data Abstraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elizabeth Glaser Pediatric AIDS Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Elizabeth Glaser Pediatric AIDS Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this data collection activity are to:

        1. Describe the baseline demographics, clinical and laboratory profile of patients who ever
           received darunavir (DRV) and/or etravirine (ETR), at the time of initiation on DRV
           and/or ETR;

        2. Describe the clinical and laboratory profile of patients who ever received DRV and/or
           ETR every 6 months from the first data collection point through 2021;

        3. Describe dynamics in HIV drug resistance mutations among patients who fail treatment on
           new regimens including DRV and/or ETR;

        4. Describe demographics, clinical and laboratory profile of young adults who transition
           out of the donation program after the age of 25 years at 12 months after their
           transition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Janssen, the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), the Partnership for Supply
      Chain Management (PFSCM), the Collaborative Initiative for Pediatric HIV Education and
      Research (CIPHER) of the International AIDS Society (IAS), and Right to Care have partnered
      to implement the New Horizons Collaborative to improve and scale-up pediatric HIV/AIDS care
      and treatment through increased awareness, research, health systems strengthening, and
      improved access to HIV/AIDS medicines. A primary source of darunavir (DRV) and etravirine
      (ETR) for pediatric populations in sub-Saharan Africa is through the New Horizons DRV/ETR
      Donation Program, which was launched in 2014. Under this program, Janssen provides DRV and/or
      ETR free of charge to eligible national HIV/AIDS programs in sub-Saharan Africa, for use in
      children and adolescents up to 25 years of age.

      Countries currently participating in the New Horizons Collaborative include: Cameroon,
      Eswatini, Ethiopia, Kenya, Lesotho, Nigeria, Rwanda, Uganda, Zambia, and Zimbabwe. Any
      country that applies and is approved for receipt of donated product will become eligible for
      this study when they begin offering donated product to patients.

      Prior to the inception of the New Horizons Collaborative, no multi-country data were
      collected regarding the demographic or clinical characteristics of the target patient
      population (i.e., children, adolescents, and young people &lt; 25 years in need of second- or
      third-line HIV/AIDS treatment). Therefore, the current activity proposes to collect
      cross-sectional demographic and clinical data at baseline and every six months for patients
      receiving DRV and/or ETR across participating New Horizons countries. This activity will
      comprise data abstraction of key demographic, clinical, laboratory and case history
      indicators and outcomes on each patient who ever received DRV and/or ETR.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical profile of patients who ever received darunavir and/or etravirine</measure>
    <time_frame>At initiation of darunavir and/or etravirine, thereafter every six months to the end of 2021, 12 months after turning age 25</time_frame>
    <description>Clinical and laboratory profiles of patients who ever received darunavir and/or etravirine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demographic profile of patients who ever received darunavir and/or etravirine</measure>
    <time_frame>At initiation of darunavir and/or etravirine</time_frame>
    <description>Age and gender of patients who ever received darunavir and/or etravirine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics in HIV drug resistance mutations</measure>
    <time_frame>At initiation of darunavir and/or etravirine, thereafter every six months to the end of 2021, 12 months after turning age 25</time_frame>
    <description>Dynamics in HIV drug resistance mutations among patients who fail treatment</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>HIV/AIDS</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who ever received darunavir and/or etravirine before turning age 25 and
        residing in the following countries: Cameroon, Eswatini, Kenya, Lesotho, Nigeria, Rwanda,
        Uganda, Zambia, Zimbabwe.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ever received darunavir and/or etravirine.

          -  Under age 25.

          -  Residing in any of the following countries: Cameroon, Ethiopia, Eswatini, Kenya,
             Lesotho, Nigeria, Rwanda, Uganda, Zambia, and Zimbabwe.

        Exclusion Criteria:

          -  Above age 25.

          -  Residing in a country not participating in the New Horizons Collaborative.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Appolinaire Tiam, MBChB, MMed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Elizabeth Glaser Pediatric AIDS Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Appolinaire Tiam, MBChB, MMed</last_name>
    <phone>202-296-9165</phone>
    <email>atiam@pedaids.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natella Rakhmanina, MD, PhD</last_name>
    <phone>202.296.9165</phone>
    <email>nrakhmanina@pedaids.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Elizabeth Glaser Pediatric AIDS Foundation/Cameroon</name>
      <address>
        <city>Yaounde</city>
        <state>Centre Region</state>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Boris Tchounga</last_name>
      <email>btchounga@pedaids.org</email>
    </contact>
    <investigator>
      <last_name>Boris Tchounga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elizabeth Glaser Pediatric AIDS Foundation/Kenya</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Masaba</last_name>
      <email>rmasaba@pedaids.org</email>
    </contact>
    <investigator>
      <last_name>Rose Masaba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elizabeth Glaser Pediatric AIDS Foundation/Lesotho</name>
      <address>
        <city>Maseru</city>
        <country>Lesotho</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Tukei</last_name>
      <email>vtukei@pedaids.org</email>
    </contact>
    <investigator>
      <last_name>Vincent Tukei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elizabeth Glaser Pediatric AIDS Foundation/Eswatini</name>
      <address>
        <city>Mbabane</city>
        <state>Hhohho</state>
        <country>Swaziland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philisiwe Khumalo</last_name>
      <email>pkhumalo@pedaids.org</email>
    </contact>
    <investigator>
      <last_name>Philisiwe Khumalo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elizabeth Glaser Pediatric AIDS Foundation/Uganda</name>
      <address>
        <city>Mbarara</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Racheal Tumwebaze</last_name>
      <email>rtumwebaze@pedaids.org</email>
    </contact>
    <investigator>
      <last_name>Racheal Tumwebaze</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Cameroon</country>
    <country>Kenya</country>
    <country>Lesotho</country>
    <country>Swaziland</country>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004 Mar 4;350(10):1023-35.</citation>
    <PMID>14999114</PMID>
  </reference>
  <reference>
    <citation>Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, Deeks SG. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS. 2008 Oct 18;22(16):2097-106. doi: 10.1097/QAD.0b013e32830f97e2.</citation>
    <PMID>18832873</PMID>
  </reference>
  <reference>
    <citation>Vaz P, Augusto O, Bila D, Macassa E, Vubil A, Jani IV, Pillon R, Sandstrom P, Sutherland D, Giaquinto C, Jordan MR, Bertagnolio S. Surveillance of HIV drug resistance in children receiving antiretroviral therapy: a pilot study of the World Health Organization's generic protocol in Maputo, Mozambique. Clin Infect Dis. 2012 May;54 Suppl 4:S369-74. doi: 10.1093/cid/cis006.</citation>
    <PMID>22544205</PMID>
  </reference>
  <reference>
    <citation>Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjanavanit S, Wannarit P, Sirisanthana T, Sirisanthana V. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. Pediatr Infect Dis J. 2007 Oct;26(10):953-6.</citation>
    <PMID>17901804</PMID>
  </reference>
  <reference>
    <citation>Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, Chi BH, Sinkala M, Kankasa C, Wilson CM, Wilfert CM, Mwango A, Levy J, Abrams EJ, Bulterys M, Stringer JS. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007 Oct 24;298(16):1888-99.</citation>
    <PMID>17954540</PMID>
  </reference>
  <reference>
    <citation>Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis. 2008 Aug;8(8):477-89. doi: 10.1016/S1473-3099(08)70180-4. Review. Erratum in: Lancet Infect Dis. 2009 Dec;9(12):736.</citation>
    <PMID>18652994</PMID>
  </reference>
  <reference>
    <citation>Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007 Mar 17;7:13.</citation>
    <PMID>17367540</PMID>
  </reference>
  <reference>
    <citation>Katabira ET, Oelrichs RB. Scaling up antiretroviral treatment in resource-limited settings: successes and challenges. AIDS. 2007 Jul;21 Suppl 4:S5-10. Review.</citation>
    <PMID>17620753</PMID>
  </reference>
  <reference>
    <citation>Janssens B, Raleigh B, Soeung S, Akao K, Te V, Gupta J, Vun MC, Ford N, Nouhin J, Nerrienet E. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics. 2007 Nov;120(5):e1134-40. Epub 2007 Oct 22.</citation>
    <PMID>17954553</PMID>
  </reference>
  <reference>
    <citation>Arastéh K, Yeni P, Pozniak A, Grinsztejn B, Jayaweera D, Roberts A, Hoy J, De Meyer S, Vangeneugden T, Tomaka F. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther. 2009;14(6):859-64. doi: 10.3851/IMP1301.</citation>
    <PMID>19812449</PMID>
  </reference>
  <reference>
    <citation>Katlama C, Clotet B, Mills A, Trottier B, Molina JM, Grinsztejn B, Towner W, Haubrich R, Nijs S, Vingerhoets J, Woodfall B, Witek J. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. 2010;15(7):1045-52. doi: 10.3851/IMP1662.</citation>
    <PMID>21041921</PMID>
  </reference>
  <reference>
    <citation>Imaz A, Llibre JM, Mora M, Mateo G, Camacho A, Blanco JR, Curran A, Santos JR, Caballero E, Bravo I, Gayá F, Domingo P, Rivero A, Falcó V, Clotet B, Ribera E. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. J Antimicrob Chemother. 2011 Feb;66(2):358-62. doi: 10.1093/jac/dkq432. Epub 2010 Dec 14. Erratum in: J Antimicrob Chemother. 2011 Sep;66(9):2194.</citation>
    <PMID>21172789</PMID>
  </reference>
  <reference>
    <citation>Fagard C, Colin C, Charpentier C, Rami A, Jacomet C, Yeni P, Vittecoq D, Katlama C, Molina JM, Descamps D, Chêne G, Yazdanpanah Y; ANRS 139 TRIO Trial Group. Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):489-93. doi: 10.1097/QAI.0b013e31824bb720.</citation>
    <PMID>22293546</PMID>
  </reference>
  <reference>
    <citation>Corrigan B, Mukui I, Mulenga L, Mthethwa N, Letsie M, Bruno S, Rakhmanina N. Characteristics of Treatment-experienced HIV-infected African Children and Adolescents Initiating Darunavir and/or Etravirine-based Antiretroviral Treatment. Pediatr Infect Dis J. 2018 Jul;37(7):669-672. doi: 10.1097/INF.0000000000001843.</citation>
    <PMID>29140932</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV/AIDS</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <keyword>Darunavir</keyword>
  <keyword>Etravirine</keyword>
  <keyword>Treatment-experienced HIV</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Young people</keyword>
  <keyword>Drug resistance mutations</keyword>
  <keyword>Cameroon</keyword>
  <keyword>Eswatini</keyword>
  <keyword>Ethiopia</keyword>
  <keyword>Kenya</keyword>
  <keyword>Lesotho</keyword>
  <keyword>Nigeria</keyword>
  <keyword>Uganda</keyword>
  <keyword>Zambia</keyword>
  <keyword>Zimbabwe</keyword>
  <keyword>Viral load</keyword>
  <keyword>Protease inhibitor</keyword>
  <keyword>Non-nucleoside reverse transcriptase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT04194021/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

